Is retatrutide legal in the UK?

Retatrutide occupies a specific regulatory position in the UK. It is not a controlled substance under the Misuse of Drugs Act, so it is not "banned" in that sense. However, it is also not a licensed medicine — it holds no marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). That distinction is the whole answer: the constraint is medicines law, not drug control law.

Because it has no licence, retatrutide cannot lawfully be marketed, prescribed or supplied as a treatment for any human condition in the UK. Material sold under the name is supplied for laboratory and in-vitro research only — not for human consumption.

A medicine can be lawfully sold for human use in the UK only once it has a marketing authorisation. That authorisation is granted after a regulator — in Great Britain, the MHRA — has reviewed full safety, quality and efficacy evidence, usually following completed clinical trials.

Retatrutide has not reached that point. It is an investigational compound developed by Eli Lilly that progressed through a published Phase 2 trial and into the TRIUMPH Phase 3 programme. At the time of writing it had no MHRA marketing authorisation, and likewise no EMA or FDA approval. Until and unless a regulator grants approval, it is not an approved medicine anywhere — a status it shares with any drug still in trials.

"Research use only" (sometimes "for in-vitro research only") is a specific designation. It signals that the material is intended for laboratory investigation rather than for administration to people or animals. In practical terms:

• It is not a medicine and carries no marketing authorisation.
• It is not intended to diagnose, treat, cure or prevent any disease.
• It is not quality-assured to the standards required of a licensed pharmaceutical for human use.
• It is supplied for in-vitro (laboratory) work, not for human or veterinary administration.

This is the framing that applies to retatrutide supplied in the UK while it remains unapproved. For the mechanism and trial background behind that status, see What Is Retatrutide? and our research-purposes-only policy.

This article is general information, not legal or medical advice. It describes a regulatory position in plain terms; it does not tell any individual what they may lawfully do, and it does not recommend human use.

Regulatory and legal positions change, and individual circumstances differ. Anyone with a specific legal question should consult a qualified professional, and anyone considering a GLP-1-class medicine for a health reason should speak to a doctor or pharmacist about an approved, prescribed option rather than an investigational compound.

Is retatrutide legal in the UK?

Retatrutide is not a controlled drug, but it is also not a licensed medicine in the UK. It has not been approved by the MHRA for human use, so it cannot be lawfully marketed, prescribed or supplied as a treatment. It is handled as a research compound for in-vitro laboratory use only.

Has the MHRA approved retatrutide?

No. As of 2026 retatrutide is an investigational compound still in clinical trials and has no marketing authorisation from the MHRA (or the EMA or FDA). Without that authorisation it is not approved for human use in the UK.

What does 'research use only' actually mean?

'Research use only' means the material is supplied for laboratory and in-vitro investigation, not for human or veterinary administration. It is not a medicine, carries no marketing authorisation, and is not intended to diagnose, treat, cure or prevent any condition.

Is retatrutide a controlled or banned substance?

Retatrutide is not listed as a controlled drug under the Misuse of Drugs Act. The relevant constraint is medicines regulation: it has no MHRA licence, so it cannot be supplied as a medicine for human use. This article is general information, not legal advice.